60 Degrees Pharmaceuticals, Inc. (SXTP)
$1.36
$-0.03
(-1.81%)
As on 12-Jun-2026 13:35EDT
Market cap
$4 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
22.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
2,659,288
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
| -33.4 | -7.8 | -57.9 | -85.8 | -- | -- | -- |
|
BSE Sensex
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
|---|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
| -92.1 | -89.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 |
|
BSE Sensex
| 9.1 | 8.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
60 Degrees Pharmaceuticals, Inc. (SXTP)
|
1.4 | 3.8 | 1.0 | -7.6 | -755.0 | -163.7 | -- | 0.0 |
| 900.9 | 55,703.0 | 6,583.9 | 2,003.3 | 14.7 | 29.9 | 39.5 | 7.2 | |
| 17.6 | 981.9 | 0.0 | -167.9 | -- | -128.7 | -- | 4.7 | |
| 25.1 | 15,440.4 | 3,900.9 | 821.0 | 23.5 | 14.4 | 19.1 | 2.7 | |
| 11.0 | 1,869.1 | 550.0 | 458.1 | -3.3 | 45.9 | 4.1 | 1.5 | |
| 3.9 | 842.1 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 13.9 | 1,803.5 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.4 | |
| 12.8 | 885.7 | 369.4 | 12.3 | 7.5 | 5 | 66 | 3.2 | |
| 2.8 | 552.7 | 4.0 | -198.4 | -5,037.7 | -166.3 | -- | 8.1 | |
| 17.3 | 1,867.3 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 2.9 |
Shareholding Pattern
View DetailsAbout 60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention... treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia. Read more
-
Chairman, CEO & President
Dr. Geoffrey Stuart Dow
-
Chairman, CEO & President
Dr. Geoffrey Stuart Dow
-
Headquarters
Washington, DC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for 60 Degrees Pharmaceuticals, Inc. (SXTP)
What is the current share price of 60 Degrees Pharmaceuticals, Inc (SXTP) Today?
The share price of 60 Degrees Pharmaceuticals, Inc (SXTP) is $1.36 (NASDAQ) as of 12-Jun-2026 13:35 EDT. 60 Degrees Pharmaceuticals, Inc (SXTP) has given a return of -85.83% in the last 1 years.
What is the current PB & PE ratio of 60 Degrees Pharmaceuticals, Inc (SXTP)?
Since, TTM earnings of 60 Degrees Pharmaceuticals, Inc (SXTP) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.07
|
0.15
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of 60 Degrees Pharmaceuticals, Inc (SXTP)?
The 52-week high and low of 60 Degrees Pharmaceuticals, Inc (SXTP) are Rs 10.77 and Rs 1.23 as of 13-Jun-2026.
What is the market cap of 60 Degrees Pharmaceuticals, Inc (SXTP)?
60 Degrees Pharmaceuticals, Inc (SXTP) has a market capitalisation of $ 4 Mln as on 05-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in 60 Degrees Pharmaceuticals, Inc (SXTP)?
Before investing in 60 Degrees Pharmaceuticals, Inc (SXTP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.